Funding Received
$13.9 Million in 2 Rounds from 4 Investors
Most Recent Funding
$4.7 Million Series B on November 2, 2012
Founded:
2002
Headquarters:
Montréal, QC
Description:
Alethia BioTherapeutics is a biotechnology company developing monoclonal antibody-based therapeutics for cancer-associated diseases.
Categories:
Biotechnology
Website:
http://www.alethiabio.com

Detailed Description

Update

Alethia BioTherapeutics, Inc., a biotechnology company, engages in the discovery and development of monoclonal antibody-based therapeutics focusing on the cancer-associated epithelial-to-mesenchymal transition, ovarian cancer, and on cancer-induced bone loss. Its products include Isogranulatimide, a G2 checkpoint inhibitor, which potentiates the response to several DNA-damaging chemotherapeutic agents; sCLU, a heterodimeric disulphide-linked glycoprotein of 449 amino acids, the over-expression of which is observed in various malignancies, including prostate, bladder, kidney, breast, colon, and lung tumors; AB-0447, an antigen that is expressed at the surface of ovarian cancer epithelial cells in greater than eighty five percent of malignant tumors; and AB-0440, a cell-surface protease-like protein, whose expression is stimulated early in osteoclast differentiation in response to RANK ligand. The company was founded in 2002 and is based in Montreal, Canada.

Current Team (9)

Update

Board Members and Advisors (3)

Update

Investors (4)

Update

Offices/Locations (1)

Update
  • Office

    141, Président-Kennedy ave.

    Suite SB-5100, Quebec,

    Montréal, QC H2X 1Y4

    CAN